NTLA News and Press, Intellia Therapeutics Inc. From 03/02/26

2026-03-02 12:15:06 ET Bank of America Securities analyst issues NEUTRAL recommendation for NTLA on March 2, 2026 03:25PM ET. The previous analyst recommendation was Neutral. NTLA was trading at $15.1 at issue of the analyst recommendation. The overall analyst consensus ...

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has...

2026-03-02 07:18:49 ET More on ARK Invest Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2025 Update AI Can't Sustain This Rate Of Return ARKG: Cathie Wood's Biotech Product Is In Rally Mode As Block rallies, just 3 fintech stocks hold A-rated momentum ...

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

2026-02-26 21:48:26 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 Intellia Therapeutics: Maintaining A Sell Rating As Platform Ri...

2026-02-26 21:47:52 ET Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript

2026-02-26 14:45:39 ET Image source: The Motley Fool. Thursday, Feb. 26, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-26 07:34:49 ET More on Intellia Therapeutics Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate Intellia Therapeutics, Inc. (NTLA) Presents at 44th Ann...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in s...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...